109 results about "Elevated blood" patented technology

Devices and methods for treating heart disease by normalizing elevated blood pressure in the left and right atria of a heart of a mammal are disclosed. Devices may include an adjustable hydraulic diameter shunt portion which can be manually adjusted in vivo. Methods are provided for adjusting the flow rate of the devices in vivo.

Devices and methods for treating heart disease by normalizing elevated blood pressure in the left and right atria of a heart of a mammal are disclosed. Devices may include an adjustable hydraulic diameter shunt portion which can be manually adjusted in vivo. Methods are provided for adjusting the flow rate of the devices in vivo.

Devices and methods for treating heart disease by normalizing elevated blood pressure in the left and right atria of a heart of a mammal are disclosed. Devices may include an adjustable hydraulic diameter shunt portion which can be manually adjusted in vivo. Methods are provided for adjusting the flow rate of the devices in vivo.

Formulations have been developed administering methscopolamine in multi-phases. In a preferred embodiment, the formulation contains methscopolamine in an immediate release. (“IR”) form and a sustained or delayed release (“DR”) form and/or poised release (“PR”) form. In another embodiment, the methscopolamine is released in a gradient, decreasing the side effects associated with rapidly elevated blood levels. In another embodiment the drug is bound to an ion-exchange resin, which can be suspended in a liquid or incorporated into a matrix for delayed, sustained and/or pulsed release. Dosage unit forms may be tablets, gels, liquids, capsules, beads, microparticles, films or lozenges. Multi-phase delivery can also be achieved through the use of a kit that provides for dosage escalation. This kit can be a blister pack or equivalent, wherein the drug is packaged so that a first dosage is taken, then sequentially larger dosages. The dosages can be the same in each unit, and instructions provided so that the correct dosage is obtained through the number of units and the time of administration or the dosages may be different, and the units ordered so dial the desired dosage administration profile is obtained when the patient takes the units in order as instructed.

A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and/or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.

Elevated blood levels of the chemokine CXCL10 polypeptide are associated with respiratory illnesses (e.g. SARS, influenza and community-acquired pneumonia) and are useful in diagnosis of patients. Methods are provided for diagnosis and treatment of patients suffering from respiratory illnesses. Methods are provided for identifying inhibitors of the CXCL10:CXCR3 axis, for use in treating patients suffering from respiratory illnesses.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

A portable pneumatic abdominal aortic tourniquet for occlusion of the abdominal descending aorta to restrict blood supply to a non-compressible arterial hemorrhage in or below the inguinal region is presented. The tourniquet includes an adjustable waist strap for securing it around the abdomen of a patient and a windlass rod connected to the waist strap to selectively tighten the strap as needed to tightly secure it to patient. A directed air bladder is mounted to the waist strap having a generally “V” shaped construction and is expanded for exerting directed pressure against the abdomen. Upon inflation of the air bladder and adjustment of the windlass, occlusion or restriction of blood flow through the abdominal descending aorta will occur which will achieve cessation of hemorrhage in or below the inguinal area or achieve other therapeutic effects like elevated blood pressure to enhance CPR or blood flow control to the lower extremities.

The invention provides a new application of berberine in the treatment of metabolic syndrome. Large-sample polycentric and randomized double-blind prospective experiments reveal the effect of berberine on metabolism of glucose and lipid and clarify the interrelation and common changes of the metabolism of glucose and lipid before and after berberine treatment. The berberine is used as a broad spectrum antibiotic and clinical drug with high efficiency and low toxicity for a long time and can be taken chronically without obvious side effect. Results of researches indicate that the berberine can help sufferers of type II diabetes mellitus combined with blood lipid abnormality regulate disorder of saccharometabolism and lipid metabolism, lower insulin resistance, avoid central obesity and elevation of blood pressure, thereby showing the positive effect of the berberine on the treatment of metabolic syndrome. The invention provides the new clinical application of berberine in the treatment of metabolic syndrome for human for the first time, which establishes the importance of the new clinical application of traditional Chinese medicine in the treatment of metabolic syndrome and provides a new basis as well, thereby helping to promote the traditional medicine of China.

The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and/or phytostanols capable of reducing cholesterol absorption in the intestine and/or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants.

The present disclosure relates to a method and a device for treating heart failure by normalizing elevated blood pressure in the left and right atria of a heart of a mammal. The present disclosure includes methods for creating and maintaining an opening in the atrial septum. Tools for making an opening and enlarging the opening are also disclosed. Use of the techniques and tools described herein prolongs the patency of an intra-atrial pressure relief opening.

The invention relates to a sea-tangle soda biscuit and a production method thereof and solves the problems of elevated blood pressure, aggravated edema and easiness weight gaining of the traditional soda biscuit. The sea-tangle soda biscuit comprises fishy smell eliminated sea-tangle flour, wheat flour, pat flour, white granulated sugar, milk powder, bicarb, ammonium bicarbonate and active dry yeast. The production method of sea-tangle soda biscuit comprises the following processes of preparation of fishy smell eliminated sea-tangle flour, raw materials processing, a first process of making paste, a first fermentation, a second process of making paste, a second fermentation, a rolling process, a forming process, a baking process, a cooling process and a packaging process and then the sea-tangle soda biscuit is obtained. Sea-tangle flour and oat flour are added to the raw materials to improve the nutritive value of soda biscuit and the prepared soda biscuit becomes a lodine supplementation, blood fat reducing, blood pressure reducing, fat absorbing prevention and diabetic prevention health food. The production method of the sea-tangle biscuit has the advantages of being simple in production technology, reasonable in working procedure and short in production cycle.

The invention aims to establish a rat model concerning pharmacodynamic screening, pharmological study and efficacy evaluation of a traditional Chinese medicine for treating concomitant hyperlipidemia and hypertension. On the basis of a hypertension rat model, model set rats are fed with high fat diet each day continuously for 2-6 weeks so as to create a hypertension complicated by hyperlipidemia model. The characteristic indicators of the model are mainly that the total cholesterol and triglyceride as well as low density lipoprotein cholesterin can be increased, and high-density lipoprotein cholesterol can be decreased while the blood pressure is increased.

The present invention relates to methods for treating or delaying the onset of pathologies associated with elevated blood glucose and/or elevated blood pressure. The methods are directed to modulating, regulating, or inhibiting the expression or activity of Connective Tissue Growth Factor (CTGF) or fragments thereof.

The invention relates to an angiotensin I converting enzyme inhibitor peptide and the analogue thereof or an ACE inhibitor formed from the salt thereof, in particular to an active single peptide separated from oyster protease decomposition product and application thereof; the active peptide is with amino acid sequence of sequence table No.1. The invention adopts enzyme catalysis technology to carry out enzymolysis on the oyster protease, takes advantage of biological molecule separation technology to carry out isolation and purification on the part with stronger ACE inhibition activity; Amino acid sequence analysis is carried out on the single peptide obtained after purification and the inhibition activity and stability of the single peptide against the ACE in vivo and in vitro are studied; the result shows that the single peptide has stronger effect of lowering blood pressure. Therefore, the active single peptide and the ramification thereof or the salt thereof can be used as long-term therapy medicine for patients with elevated blood pressure or can be used as food additive to be made into health foods.

A method for treating or preventing an elevated blood lipid level-related diseases such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and hepatic diseases in a mammal, which comprises administering thereto an effective amount of tannin, gallic acid or ellagic acid.

The present invention relates to a C-triaryl glucoside SGLT-2 inhibitor shown as formula (I), preparation methods therefor, pharmaceutical compositions thereof and uses thereof for treating diseases that benefit from inhibiting SGLT-2. Such diseases are diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood level of fatty acids, elevated blood level of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, atherosclerosis or hypertension. The compounds of the present invention have strong inhibition activity against SGLT-2, higher selectivity, improved drug metabolism properties in oral treatment, and good druggability.